Prosecution Insights
Last updated: April 17, 2026
Application No. 17/114,030

Colloidal Suspensions of Plant Extracts in Aqueous Solutions

Non-Final OA §103
Filed
Dec 07, 2020
Examiner
BOECKELMAN, JACOB A
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
unknown
OA Round
6 (Non-Final)
36%
Grant Probability
At Risk
6-7
OA Rounds
3y 1m
To Grant
83%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allow Rate
86 granted / 237 resolved
-23.7% vs TC avg
Strong +46% interview lift
Without
With
+46.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
96 currently pending
Career history
333
Total Applications
across all art units

Statute-Specific Performance

§101
13.6%
-26.4% vs TC avg
§103
52.1%
+12.1% vs TC avg
§102
12.3%
-27.7% vs TC avg
§112
16.6%
-23.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 237 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/04/2025 has been entered. Response to Amendment Applicant's amendment and argument filed 11/04/2025 in response to the final rejection, are acknowledged and have been fully considered. Any previous rejection or objection not mentioned herein is withdrawn. Claims 1-19 are pending of which claims 11-19 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/09/2022. Claims 1-10 are being examined on the merits. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 1-5 and 7-10 are rejected under 35 U.S.C. 103 as being unpatentable over Ben Geiling and Tom Shipley (WO2019104442A1), hereinafter Geiling. This a new rejection based on the amendments filed on 11/04/2025. Regarding claim 1, 3 and 10, Geiling teaches “an emulsion comprising at least one cannabis or cannabis derived compound, a carrier oil, and an aqueous solution” (see claim 13) and teaches a variety of carrier oils to be chosen from, of which different medium chain fatty acids such as (e.g., caproic acid, caprylic acid, capric acid, lauric acid) and long- chain triglycerides (LCT oil), long-chain fatty acids (e.g., myristic acid, palmitic acid, stearic acid, arachidic acid, linoleic acid), can be selected (see claim 14). Geiling teaches “[0090] Extraction in natural products chemistry is a separation process comprising the separation of a substance from a matrix of natural materials and includes liquid-liquid extraction, solid phase extraction and what is commonly referred to as super-critical extraction. The distribution of any given compound or composition (hereinafter desired material) between two phases is an equilibrium condition described by partition theory. This is based on exactly how the desired material moves from a first solution, typically water or other material capable of dissolving a desired material with a first solubility of the desired material, into second material. Regarding claim 2, Geiling teaches formulations comprising terpenes (see claim 2). Regarding claim 4, Geiling teaches “emulsions stabilized by surfactants or other types of stabilizing agents phospholipids, amphiphilic proteins, or polysaccharides” (see 0068). Regarding claim 5, Geiling teaches purified water (see 0073) and acids (see above). Regarding claim 7, Geiling teaches “most of historical cannabis beverages were prepared by boiling or grinding cannabis leaves, combining with water, milk, alcohol, or another biocompatible matrix and, optionally, mixing with herbal or other plant-based compositions to form the final consumable” (see 0014). Regarding claim 8, Geiling teaches ultrasonication (see 0069-0070). Regarding claim 9, Geiling teaches supercritical CO2 extraction (see 0092). Therefore it would have been obvious to persons having skill in the art and before the effective filing date to create the instant invention because Geiling teaches of cannabinoid compositions which consists of emulsions and carrier oils. The carrier oil would act as the emulsifying agent and persons having skill in the art could select one of the acid medium/long chain fatty acids which would help to create an acid solution. Geiling also teaches that it is an intention to dissolve the active components in solution and thus the instant invention is prima facie obvious. Claim 6 is rejected under 35 U.S.C. 103 as being unpatentable over Ben Geiling and Tom Shipley (WO2019104442A1) as applied to claims 1-5 and 7-10 above, and further in view of Stanton (US4284657A). This a new rejection based on the amendments filed on 11/04/2025. Geiling teaches the instant invention, however is silent on the colloidal mixture comprising acidic aqueous solutions which comprise of the components of claim 6. Stanton teaches of fluidized oleoresin compositions and teaches wherein phosphoric acid may be useful for providing low pH aqueous mixtures and to act as a preserving agent in oleoresin compositions (see column 4 lines 31-35). Therefore it would have been obvious to persons having ordinary skill in the art and before the effective filing date to use phosphoric acid in the aqueous solution described by Geiling for creating colloidal/oleoresin compositions because it can lower the pH and act as a preservative as discussed by Stanton. Response to Arguments Applicant’s arguments with respect to claims 1-10 have been considered but are moot because the new ground of rejection does not rely on the same reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion Currently no claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JACOB ANDREW BOECKELMAN whose telephone number is (571)272-0043. The examiner can normally be reached Monday-Friday 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Terry McKelvey can be reached at 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. JACOB A BOECKELMAN Examiner, Art Unit 1655 /ANAND U DESAI/ Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Dec 07, 2020
Application Filed
Oct 03, 2022
Non-Final Rejection — §103
Apr 06, 2023
Response Filed
Aug 24, 2023
Final Rejection — §103
Feb 14, 2024
Interview Requested
Feb 29, 2024
Applicant Interview (Telephonic)
Feb 29, 2024
Examiner Interview Summary
Mar 08, 2024
Request for Continued Examination
Mar 11, 2024
Response after Non-Final Action
Mar 26, 2024
Non-Final Rejection — §103
Aug 28, 2024
Response Filed
Sep 16, 2024
Non-Final Rejection — §103
Mar 25, 2025
Response Filed
Apr 22, 2025
Final Rejection — §103
Nov 04, 2025
Request for Continued Examination
Nov 05, 2025
Response after Non-Final Action
Dec 15, 2025
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599630
SERUM EXOSOME WITH HIGH OSTEOGENESIS AND HIGH ANGIOGENESIS, PREPARATION METHOD, AND APPLICATION THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12594303
COMPOSITION COMPRISING EXOSOMES DERIVED FROM INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL PROGENITOR FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
2y 5m to grant Granted Apr 07, 2026
Patent 12594315
Use of Liriodendron Chinense (Hemsl.) Sarg. or Extract thereof in the Preparation of Medicament for Reducing Serum Uric Acid Level and Preventing and Treating Uric Acid Nephropathy
2y 5m to grant Granted Apr 07, 2026
Patent 12575575
METHOD FOR PREPARING MUSHROOM ANTIBACTERIAL AGENT AND ANTIBACTERIAL AGENT MADE THEREFROM
2y 5m to grant Granted Mar 17, 2026
Patent 12551522
HERBAL COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING SARS-COV-2 VIRUS INFECTION
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

6-7
Expected OA Rounds
36%
Grant Probability
83%
With Interview (+46.5%)
3y 1m
Median Time to Grant
High
PTA Risk
Based on 237 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month